Literature DB >> 18812768

Genetic ablation of CD36 induces age-related corneal neovascularization.

Bupe R Mwaikambo1, Florian Sennlaub, Huy Ong, Sylvain Chemtob, Pierre Hardy.   

Abstract

PURPOSE: Corneal avascularity is tightly regulated by a balance between angiogenic and antiangiogenic factors (angiogenic privilege). In the current study, we tested the hypothesis that the CD36+/+ antiangiogenic receptor contributes toward the maintenance of corneal avascularity.
METHODS: Corneas of CD36 wild-type (CD36) and knockout (CD36) mice aged 4, 16, 52, and 78 weeks were histologically evaluated for corneal haze and neovascularization (NV). Quantitative real-time polymerase chain reaction was performed on corneal tissue from CD36+/+ and CD36-/- mice aged 4 and 52 weeks to examine the effect of CD36 deficiency on expression of relevant angiogenic factors.
RESULTS: Corneal haze and NV were absent in CD36+/+ mice at all ages. Conversely, corneal haze and NV were evident at 52 and 78 weeks in CD36-/- mice, and the latter demonstrated a significant increase in vessel density at 52 and 78 weeks. Interestingly, compared with CD36+/+ mice, in the corneas of 52-week-old CD36-/- mice, thrombospondin-1 messenger RNA was repressed, and vascular endothelial growth factor A, c-Jun N-terminal kinase-1, and c-Jun levels were robustly upregulated.
CONCLUSIONS: CD36-/- mice develop corneal NV that increases in severity with age, thus accentuating the role of CD36 in preserving corneal avascularity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812768     DOI: 10.1097/ICO.0b013e31817780b6

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

Review 1.  Animal models of ocular angiogenesis: from development to pathologies.

Authors:  Chi-Hsiu Liu; Zhongxiao Wang; Ye Sun; Jing Chen
Journal:  FASEB J       Date:  2017-07-24       Impact factor: 5.191

Review 2.  Corneal neovascularization: an anti-VEGF therapy review.

Authors:  Jin-Hong Chang; Nitin K Garg; Elisa Lunde; Kyu-Yeon Han; Sandeep Jain; Dimitri T Azar
Journal:  Surv Ophthalmol       Date:  2012-09       Impact factor: 6.048

3.  Spontaneous bacterial keratitis in CD36 knockout mice.

Authors:  Julia Klocke; Rita N Barcia; Susan Heimer; Elke Cario; James Zieske; Michael S Gilmore; Bruce R Ksander; Meredith S Gregory
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-05       Impact factor: 4.799

Review 4.  Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).

Authors:  William Stevenson; Sheng-Fu Cheng; Mohammad H Dastjerdi; Giulio Ferrari; Reza Dana
Journal:  Ocul Surf       Date:  2012-01-25       Impact factor: 5.033

5.  Increased CD36 expression signals monocyte activation among patients with type 2 diabetes.

Authors:  Yijuan Sun; Marina Scavini; Robert A Orlando; Glen H Murata; Karen S Servilla; Antonios H Tzamaloukas; Ronald Schrader; Edward J Bedrick; Mark R Burge; Nada A Abumrad; Philip G Zager
Journal:  Diabetes Care       Date:  2010-06-14       Impact factor: 19.112

6.  Hypoxia up-regulates CD36 expression and function via hypoxia-inducible factor-1- and phosphatidylinositol 3-kinase-dependent mechanisms.

Authors:  Bupe R Mwaikambo; Chun Yang; Sylvain Chemtob; Pierre Hardy
Journal:  J Biol Chem       Date:  2009-07-29       Impact factor: 5.157

7.  Low-bone-mass phenotype of deficient mice for the cluster of differentiation 36 (CD36).

Authors:  Olha Kevorkova; Corine Martineau; Louise Martin-Falstrault; Jaime Sanchez-Dardon; Louise Brissette; Robert Moreau
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

8.  Lymphocytic Microparticles Modulate Angiogenic Properties of Macrophages in Laser-induced Choroidal Neovascularization.

Authors:  Houda Tahiri; Samy Omri; Chun Yang; François Duhamel; Suzanne Samarani; Ali Ahmad; Mark Vezina; Martin Bussières; Elvire Vaucher; Przemyslaw Sapieha; Gilles Hickson; Karim Hammamji; Réjean Lapointe; Francis Rodier; Sophie Tremblay; Isabelle Royal; Jean-François Cailhier; Sylvain Chemtob; Pierre Hardy
Journal:  Sci Rep       Date:  2016-11-22       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.